eNauka - pregled

Pregled prema Autor Hanes, Vladimir

Prikaz rezultata 1 do 5 od 5
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2018Abstract PD3-10: Safety results from a randomized, double-blind, phase 3 study of ABP 980 compared with trastuzumab in patients with breast cancer (✓)Kolberg, Hans-Christian; Demetriou, Georgia S; Zhang, Nan; Tomasevic, Zorica I  ; Hanes, VladimirKonferencijski rad
Mp kategorija će biti prikazana naknadno.
2020Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study (✓)Kolberg, Hans-Christian; Colleoni, Marco A; Sawa-Demetriou, G; Santi, Patricia Xavier; Tesch, Hans; Fujiwara, Yasuhiro; Tomasevic, Zorica I  ; Hanes, VladimirNaučni članak
21aM21a - Rad u međ. časopisu izuzetnih vrednosti
2018Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indicationsKolberg, Hans-Christian; Tomasevic, Zoran M; Demetriou, Georgia S; von, Minckwitz Gunter; Fujiwara, Yasuhiro; Ponomarova, O; Tesch, Hans; Santi, Patricia Xavier; Hanes, VladimirKonferencijski rad
Mp kategorija će biti prikazana naknadno.
2018Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial (✓)von, Minckwitz Gunter; Colleoni, Marco A; Kolberg, Hans-Christian; Morales, Serafin; Santi, Patricia Xavier; Tomasevic, Zorica I  ; Zhang, Nan; Hanes, VladimirNaučni članak
21aM21a - Rad u međ. časopisu izuzetnih vrednosti
2019Matching the critical function of the biosimilar ABP 980 and trastuzumab: Totality of evidence and scientific justification for extrapolation across trastuzumab indicationsKolberg, Hans-Christian; Colleoni, Marco A; Tomasevic, Zoran M; Ponomarova, O; McBride, HJ; Tesch, Hans; Hanes, VladimirKonferencijski rad
Mp kategorija će biti prikazana naknadno.